| WNT signaling in cardiac and vascular disease S Foulquier, EP Daskalopoulos, G Lluri, KCM Hermans, A Deb, ... Pharmacological reviews 70 (1), 68-141, 2018 | 347 | 2018 |
| AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation R Gélinas, F Mailleux, J Dontaine, L Bultot, B Demeulder, A Ginion, ... Nature communications 9 (1), 374, 2018 | 216 | 2018 |
| Towards standardization of echocardiography for the evaluation of left ventricular function in adult rodents: a position paper of the ESC Working Group on Myocardial Function S Zacchigna, A Paldino, I Falcão-Pires, EP Daskalopoulos, M Dal Ferro, ... Cardiovascular research 117 (1), 43-59, 2021 | 154 | 2021 |
| AMPK in cardiac fibrosis and repair: actions beyond metabolic regulation EP Daskalopoulos, C Dufeys, L Bertrand, C Beauloye, S Horman Journal of Molecular and Cellular Cardiology 91, 188-200, 2016 | 127 | 2016 |
| Myofibroblasts in the infarct area: concepts and challenges EP Daskalopoulos, BJA Janssen, WM Blankesteijn Microscopy and Microanalysis 18 (1), 35-49, 2012 | 113 | 2012 |
| Sodium-myoinositol cotransporter-1, SMIT1, mediates the production of reactive oxygen species induced by hyperglycemia in the heart A Van Steenbergen, M Balteau, A Ginion, L Ferté, S Battault, ... Scientific reports 7 (1), 41166, 2017 | 89 | 2017 |
| Targeting the Wnt/frizzled signaling pathway after myocardial infarction: a new tool in the therapeutic toolbox? EP Daskalopoulos, KCM Hermans, BJA Janssen, WM Blankesteijn Trends in cardiovascular medicine 23 (4), 121-127, 2013 | 52 | 2013 |
| Diurnal rhythms of serum and plasma cytokine profiles in healthy elderly individuals assessed using membrane based multiplexed immunoassay R Altara, M Manca, KCM Hermans, EP Daskalopoulos, HPBL Rocca, ... Journal of translational medicine 13, 1-8, 2015 | 49 | 2015 |
| AMPK in cardiovascular diseases EP Daskalopoulos, C Dufeys, C Beauloye, L Bertrand, S Horman AMP-activated Protein Kinase, 179-201, 2016 | 48 | 2016 |
| Stress is a critical player in CYP3A, CYP2C, and CYP2D regulation: role of adrenergic receptor signaling pathways EP Daskalopoulos, F Malliou, G Rentesi, M Marselos, MA Lang, ... American Journal of Physiology-Endocrinology and Metabolism 303 (1), E40-E54, 2012 | 48 | 2012 |
| The Janus face of myofibroblasts in the remodeling heart KCM Hermans, EP Daskalopoulos, WM Blankesteijn Journal of Molecular and Cellular Cardiology 91, 35-41, 2016 | 39 | 2016 |
| Interventions in Wnt signaling as a novel therapeutic approach to improve myocardial infarct healing KCM Hermans, EP Daskalopoulos, WM Blankesteijn Fibrogenesis & tissue repair 5, 1-11, 2012 | 39 | 2012 |
| AMPKα1 deletion in myofibroblasts exacerbates post-myocardial infarction fibrosis by a connexin 43 mechanism C Dufeys, EP Daskalopoulos, D Castanares-Zapatero, SJ Conway, ... Basic research in cardiology 116, 1-20, 2021 | 36 | 2021 |
| D2-dopaminergic receptor-linked pathways: critical regulators of CYP3A, CYP2C, and CYP2D EP Daskalopoulos, MA Lang, M Marselos, F Malliou, M Konstandi Molecular Pharmacology 82 (4), 668-678, 2012 | 33 | 2012 |
| UM206, a selective Frizzled antagonist, attenuates adverse remodeling after myocardial infarction in swine A Uitterdijk, KCM Hermans, DPM de Wijs-Meijler, EP Daskalopoulos, ... Laboratory investigation 96 (2), 168-176, 2016 | 30 | 2016 |
| Dopamine D2-Receptor Antagonists Down-Regulate CYP1A1/2 and CYP1B1 in the Rat Liver P Harkitis, EP Daskalopoulos, F Malliou, MA Lang, M Marselos, ... PLoS One 10 (10), e0128708, 2015 | 27 | 2015 |
| Recommendations for robust and reproducible preclinical research in personalised medicine V Fosse, E Oldoni, F Bietrix, A Budillon, EP Daskalopoulos, M Fratelli, ... BMC medicine 21 (1), 14, 2023 | 26 | 2023 |
| Loss of mouse P2Y6 nucleotide receptor is associated with physiological macrocardia and amplified pathological cardiac hypertrophy S Clouet, L Di Pietrantonio, EP Daskalopoulos, H Esfahani, M Horckmans, ... Journal of Biological Chemistry 291 (30), 15841-15852, 2016 | 26 | 2016 |
| Factors modulating COVID-19: A mechanistic understanding based on the adverse outcome pathway framework LA Clerbaux, MC Albertini, N Amigo, A Beronius, GFG Bezemer, ... Journal of Clinical Medicine 11 (15), 4464, 2022 | 25 | 2022 |
| Cardiac (myo) fibroblast: novel strategies for its targeting following myocardial infarction E P Daskalopoulos, K CM Hermans, W Matthijs Blankesteijn Current pharmaceutical design 20 (12), 1987-2002, 2014 | 24 | 2014 |
